Breaking News

Financial Report: Baxter

April 17, 2014

Revenues up 15% boosted by Gambro acquisition


1Q Revenues: $4.0 billion (+15%)

1Q Earnings: $556 million (+1%)

Comments: BioScience revenues were $1.6 billion, up 5%, driven by growth of ADVATE and FEIBA, improved U.S. sales of plasma-based therapeutics including GAMMAGARD LIQUID, and milestone payments related to ongoing collaborations with governments on flu vaccine development. Medical Products sales increased 22% to $2.3 billion, augmented by the Gambro acquisition, which contributed $400 million. R&D expenses were $313 million up 27%.
blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus